Rituximab Cuts Relapse Risk in MCD, FSGS in TURING Trial

At the European Renal Association (ERA) Congress in Glasgow, Scotland, results from the TURING trial offered long-awaited evidence that rituximab can meaningfully reduce relapse rates in adults with minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS).

These conditions have been historically managed with prolonged, high-dose corticosteroid courses, carrying a substantial burden of adverse effects. In this episode of Kidney Compass, host Brendon Neuen, MBBS, PhD, spoke with Lisa Willcocks, MBBChir, MRCP, PhD, a consultant nephrologist who leads the primary glomerular disease service at Addenbrooke's Hospital in Cambridge, United Kingdom, about the trial she presented as a late-breaking clinical result at the congress.

Read more: https://www.hcplive.com/view/kidney-compass-turing-trial-rituximab-relapse-risk-mcd-fsgs